Citigroup analyst Fatima Boolani maintains Check Point Software (NASDAQ:CHKP) with a Sell and lowers the price target from $122 to $120.
Regulus Therapeutics Q2 EPS $(0.08), Inline
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 65.22 percent increase over losses of $(0.23) per share from the same period last